Mar-2022 From the Podium to the Clinic
The main focus of webinar is to share the topline data presented at ECCO 2022 and asses their impact in IBD clinical practice in 3 key areas, (1) Imaging and non-invasive monitoring, (2) Drug strategies & treatment updates and (3) New drug around the corner
Speakers: Prof Silvio Danese, Prof Laurent Peyrin-Biroulet and Prof Britta Siegmund
Oct-2021 Evolution of Endpoints: The Changing Paradigm in Trials for Active UC (by Prof. Travis) Managing Active UC Flares with Second Generation Corticosteroid: Real World Experience (by Prof. Leung)
Speakers:
Professor Simon Travis, Translational Gastroenterology Unit and Linacre College, Oxford, UK
Professor WK Leung, The University of Hong Kong, Hong Kong
In this recording, IBD experts from UK, HK and India shared their view and clinical experience in using either topical or systemic corticosteroid in managing active UC. The role of second generation corticosteroids was discussed among panelists regarding the selection of patients and the treatment strategy.
Jan-2022 Post-operative recurrence of Crohn’s Disease
Speaker: Prof Matthieu Allez (Université de Paris, France)
This IBD Mirror highlights the high recurrence of Crohn’s disease in the operative phase (up to 50% in 5 years) even in the contemporary monitoring programme. Prof Matthieu postulates that diverse histological and molecular abnormalities at the proximal margin of the surgical specimen are associated with an increase risk of post-operative recurrence. Many genes are upregulated even in endoscopic remitters, suggesting that endoscopic remission is not equal to molecular remission. Surgery does not correspond to a complete resetting of the disease in most patients.
Dec-2021 Multinational research into clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Speaker: Prof Simon Travis, UK
Last year Ferring organized 2 global advisory board meetings with 11 international experts to understand current thinking and clinical decision making in IBD. In this clip, Prof Simon Travis explains how these meetings have been conducted and the key learnings. The current management approach for mild-to-moderate UC was found to be guided primarily by the patient’s perspectives and goals, alongside assessment of their medical and disease history.
Dec-2021 Benefits of gastrointestinal ultrasound for tight monitoring and control of IBD
Speaker: Prof Gerald Rogler (University Hospital of Zurich at the airport)
Professor Rogler demonstrated the rationale of performing ultrasound to timely identify whether the patient has achieved remission, or currently is having a flare or something else, that requires dosing adjustment (or withdrawal) before diagnostic investigation is done. He further emphasized the convenience and the cost effectiveness of utilizing ultrasound for tight monitoring and control IBD, even as a clinical endpoint of therapeutic response. Four cases are demonstrated live in the use of intestinal ultrasound: 1) patient in remission reducing treatment at their request, 2) patient stoma with new flare, 3) patient with new flare, 4) patient on biologic with perianal fistula.
Dec-2021 Big data in IBD: Big progress for clinical practice
Speaker: Prof Séverine Vermeire (University Hospitals and KU Leuven, Belgium)
In this short clip, Professor Séverine Vermeire provided a high-level overview of using big data (from electronic medical record, imaging files, and molecular omics study) to investigate the aetiology of complex disease such as IBD in the clinical practice. She further illustrated how stratifying patients towards therapeutic purposes and prognostication, and practical significance of big datasets such as disease cohorts and biobanks to integrate with IBD-omics data.
Dec-2021 The evidence for Pentasa 2-4g sachets or tabs based on a new meta-analysis published in CMRO
Speaker: Professor Simon Travis, Translational Gastroenterology Unit, Linacre College, Oxford, UK
Professor Simon Travis provided a deep dive of a new systemic review & meta-analysis on efficacy and safety of oral Pentasa in mild-to-moderate ulcerative colitis published in Current Medical Research and Opinion 2021. He proffered new insight derived from this study regarding relevant endpoints and comparisons vs placebo and other 5-ASAs. This paper concludes Pentasa was similarly effective to Eudragit-S (Asacol), Eudragit-L (Salofalk), and MMX mesalazine (Mezavant) at inducing remission at low (2.25-3 vs 2.4-3 g/day, respectively) and higher doses (4 vs 4.8 g/day). When including observational data, Pentasa was significantly better in maintaining remission vs both sulphasalazine and Eudragit-S mesalazine.
Nov-2021 Faecal microbiota transplant (FMT) for IBD – hope or hype?
Speaker: Dr. Samuel Costello (The Queen Elizabeth Hospital, Adelaide, Australia)
In this 12-min clip, Dr. Costello explained why microbial therapies such as faecal microbiota transplant (FMT) are considered for IBD management, illustrating the replacement of critical microbes to achieve functional restoration. He further detailed nuances of different FMT routes across 4 RCTs. To conclude, Dr. Costello stressed microbial based therapies can induce remission in UC with promise in Crohn’s disease, but at present more data are required. Second generation treatments are being developed which aim to further improve the efficacy of FMT.
Oct-2021 Calprotectin for monitoring IBD patients
Speaker: Dr Johan Burisch (Hvidovre Hospital Denmark)
In this IBD Mirror Series #9, Dr. Burisch explains the usefulness (and the limitation) of faecal calprotectin to manage IBD at various stages of disease, and as a predictive biomarker to early detect disease flares even 3 months before clinical presentations. Smart phone enabled calprotectin home test is also illustrated to embrace a comprehensive eHealth monitoring strategy.
Sep-2021 IBD and Venous Thromboembolism (10min)
Speaker: Prof Walter Ageno (Emergency Department and Thrombosis Center, University of Insubria, Varese, Italy)
Based on updated guidelines of American Society of Hematology 2020, Prof Ageno walked us through key topics in risk of venous thromboembolism among IBD patients, including the use of anti-coagulant as part of prophylaxis considered when the disease is active or in the presence of additional risk factors. Issues such as duration of anti-coagulant, what provoking factors to be considered when stopping anti-coagulants, splanchnic vein thrombosis are discussed.
Sep-2021 T2T In Mild-to-Moderate UC: Can We Achieve Long-Term Disease Modification?
Speakers: Prof. Alisa Hart (UK), Dr. Nik Raihan (Malaysia), Prof. Shu-Chen Wei (Taiwan), Prof. John Ding (Australia)
This talk begins with Prof Hart’s keynote speech on evolving therapeutic goals in UC, especially in the out-patient setting, and how she chooses the best option for her patients by adopting a holistic approach. Then Dr. Raihan further elaborated the role of histological assessment for treatment response as histological activity is more predictive of clinical relapse and corticosteroid use compared to endoscopic findings alone. A series of illustrative clinical cases are presented to show how T2T strategies are deployed in the real-world setting.
IBD Undone: New Update in T2T Strategies in UC (by Prof. Alison Hart) 2’ – 28’
Targeting Histological Healing in UC: From the Pathologist Perspective (by Dr. Nik Raihan) 29’ – 46’
Case Presentations on UC & Panel Discussion (by Prof. Shu-Chen Wei and Prof. John Ding) 47’ – 90’
Aug-2021 Real World Use of Terlipressin in the Era of Precision Medicine
Speakers: Prof. Florence Wong (University of Toronto, Canada), Dr. dr. Muhammad Begawan Bestari, SpPD-KGEH, M.Kes (Indonesia), Dr. James Fung (University of Hong Kong)
In the amidst of public health crisis when endoscopic intervention is deferred, the use of vasoconstrictor terlipressin has become more critical in saving lives. In this talk, distinguished speakers from North America and Asia will shed clinical insight of how to unleash the value of terlipressin in the real world setting. The moderator of the webinar was Prof Guan Huei Lee from Singapore.
Personalizing Terlipressin in Type 1 HRS and BOV (by Prof. Florence Wong) 3:13 – 38:32
BOV panel: How I do it in Indonesia (by Prof. Muhammad Begawan Bestari) 38:33 – 61:08
HRS panel: How I do it in Hong Kong (by Dr. James Fung) 61:09 – 84:30
Q & A session (all speakers) 84:31 – 102:09
June-2021 Dietary guidance in IBD: from pathogenesis to optimised nutrition (17min)
Speakers: Prof Arie Levine, Tel Aviv University Israel, and the famous Chef Daniel Shalit
Illustrated by Chef Shalit in the preparation of healthy IBD meal, Prof. Levine explained specific protein intake and its association with IBD risk based on clinical studies, advising what dietary recommendations for IBD patients (CD and UC respectively) by IOIBD, alluding to triggering dietary factors on host barrier and immune system in the pathogenesis of CD, effects of Western diet. Phased dietary recommendation in CDED will be highlighted.
May-2021 Current Clinical Practice of Treat to Target Strategy in IBD Management
Speakers:Prof ByongDuk Ye (Korea) and Prof Wai Keung Leung (Hong Kong)
Treat to Target in Real Life Practice (Prof Byong Duk Ye) 3:00 – 37:05
Key Strategy for Dose-Optimization of 5ASA (Prof. Wai Keung Leung) 37:06 – 70:20
Discussion and Q & A (All speakers) 70:22 – 83:00
June-2021 The future of endoscopy in UC management: from disease assessment to cancer treatment
Speakers: Prof Raf Bisschops, Head of Endoscopy (UZ Leuven, Belgium) Dr Tom Eelbode, Imaging Researcher (UZ Leuven, Belgium)
IBD endoscopic experts Prof. Bisschops, together with imaging researcher Dr. Eelbode, illustrated in this 23 min clip the strategies to decrease colorectal cancer via proper driven surveillance techniques, and how advanced AI driven imaging can help to assess better mucosal healing, improve detection of early neoplastic lesions and characterization of lesions that enables endoscopic resection.
May-2021 Revolutionize IBD Clinical Practice with Budesonide MMX
Speakers: Dr. Juanda Leo Hartono, Director of IBD unit, National University Hospital Singapore
Dr. Juanda shared the ins and outs of Budesonide MMX such as MMS delivery system, pharmacokinetics, especially in the case of retractable UC cases. Clinical evidence of Budesonide MMX in pivotal trials and recent publications in UC management using Budesonide MMX was illustrated.
June-2021 Towards Disease Clearance in Mild-Moderate Ulcerative Colitis: Are We Ready?
Introduction and setting the scene (Emeritus Professor Khean Lee Goh) 3:00 – 6:17
New Strategies in the Management of Ulcerative Colitis (Prof Rupert Leong) 6:17 – 40:38
Case Presentation from Singapore (Dr Malcolm Tan) 41:20 – 51:40
Case Presentation from The Philippines (Professor Jose D Sollano) 51:40 – 68:40
Q and A (All speakers) 68:40 – 84:00
Speakers:
Prof Rupert Leong, University of Sydney and Macquarie University, Australia
Dr Malcolm Tan, Singapore General Hospital, Singapore
Professor Jose D Sollano, University of Santo Tomas Faculty of Medicine and Surgery, The Philippines
12-May-2021 Actors and factors in resolving inflammation
Speaker: Prof. Silvio Danese, Consultant Gastroenterologist, IBD Center, Milan, Italy
Prof. Danese talks about the resolution of inflammation as the return to the tissue homeostasis, and provides his expert reflections on the relevance of resolution to IBD management.
9-April-2021 COVID19 Vaccination in IBD
Speakers: Dr. Juanda Leo Hartono (Singapore), Prof. Ivan Hung (Hong Kong), Prof. David Allen (Singapore)
This webinar invites 3 distinguished experts to walk the audience through updated clinical impact of COVID19 on IBD patients, as well as the interaction of COVID19 vaccines with unique immunogenicity in IBD patients.
“Video Link” Dr. Juanda Leo Hartono
“Video Link” Prof. Ivan Hung
“Video Link” Prof. David Allen
“Video Link” Q&A session
31-Mar-2021: Microscopic Colitis: Describing a Novel Diarrhoeal Pathomechanism
Speaker: Professor Andreas Münch
Microscopic colitis is now surpassing ulcerative colitis and Crohn’s disease in incidence in some advanced countries. While histology makes the diagnosis but does not help to understand the pathogenesis. Prof. Münch presented a novel molecular mechanism – malabsorptive, to be a treatment target for microscopic colitis.
08-Mar-2021: Revolutionising Clinical Practice with Remote Monitoring
Speaker: Dr. Alissa Walsh, Consultant Gastroenterologist, Oxford University Hospitals NHS Trust, Oxford, UK
Dr. Walsh exemplified a software, web-based platform in Oxford called TrueColours IBD for remote monitoring of IBD care, and invited a patient – Zosia Krakewska – on the benefits of remote monitoring/e-medicine to patients.
13-Nov-2020: IBD Management Beyond the Clinic webinar is the 1st tripartite collaboration between Ferring, Patient Society and Healthcare Professionals to provide a holistic education on IBD care.
Event moderator: Ms Nidhi Swarup, President, Crohn’s & Colitis Society of Singapore.
The focus of this webinar is IBD nursing support, patient counseling, and role of nutrition in IBD care.
IBD Nursing (Lydia White) from John Radcliffe Hospital, Oxford UK “Video Link”
Role of Nutrition in IBD (Dr Ennaliza Salazar) Consultant Gastroenterologist, Singapore General Hospital “Video Link”
6-May-2020: COVID-19 and IBD – The NUH Experience:
in this webinar, speakers (Dr. David Ong, Dr Michelle Gowans, and Dr. Juanda Leo from National University Hospital Singapore) share their insight and experience on general management, IBD medications, and diarrhea and IBD care in COVID-19 patients and what to advise patients.
13-Nov-2020: IBD Management Beyond the Clinic:
Advanced IBD Nursing & Nutrition, the 1st tripartite collaboration between Ferring, Patient Society and Healthcare Professionals to provide a holistic education on IBD care, by Lydia White (IBD nurse clinician, UK), Dr. Ennaliza Salazar (Singapore General Hospital, Singapore) moderated by Nidhi Swarup, President of Crohn’s & Colitis Society of Singapore.
12-Sep-2020: Excellence in Clinical Practice of Ulcerative Colitis Management (EPIC)
on IBD’s changing clinical course of UC patients, and Treat to Target, with challenging cases in UC, by Prof Alex Leow (Malaysia), Prof Siew Ng (Hong Kong) and Prof Zhihua Ran (China).
External webinar (open access)
17-Apr-2020: COVID-19 & IBD:
Treatment, Service and Research: IBD Expert Charlie Lees talks about COVID-19 and IBD treatment, service and research. Charlie Lees is a consultant gastroenterologist at the Western General Hospital, Edinburgh and honorary senior lecturer at the University of Edinburgh. Organized by United European Gastroenterology.
23-Mar-2020: What IBD patients need to know about COVID-19:
Drs. David Rubin (The University of Chicago Medicine) and Andrew Grossman (Children’s Hospital of Philadelphia) join Laura Wingate, the Foundation’s Senior Vice President for Education, Support, & Advocacy, to review what IBD patients need to know about the coronavirus (COVID-19). Organized by Crohn’s & Colitis Foundation
